Navigation Links
At the 2007 Alzheimer's Association International Conference on the,Prevention of Dementia - Neurochem's U.S. Principal Investigator,Presents Update on Tramiprosate (Alzhemed)

WASHINGTON, DC, June 11, 2007 /PRNewswire-FirstCall/ - Paul S. Aisen, M.D., Professor of Neurology and Medicine at Georgetown University Medical Center, and principal investigator in the United States of Neurochem Inc.'s North American Phase III clinical trial for tramiprosate (ALZHEMED(TM)) will present today an update on Neurochem's investigational product candidate for the treatment of Alzheimer's disease (AD). The presentation by Dr. Aisen will take place at the Intervention and Treatment Session, scheduled from 2:30 - 4:30 P.M. (ET), at the Alzheimer's Association International Conference on Prevention of Dementia in Washington, DC. In his presentation entitled, A Phase III Study of the Efficacy, Safety and Disease Modification Effect of Tramiprosate in Mild-to-Moderate Alzheimer's Disease, Dr. Aisen will review the Phase III clinical trial and provide an update.

Neurochem announced in April 2007 that an adjustment to the initial statistical model, as set out in the statistical plan, would be necessary to provide accurate results. The procedure to arrive at a reliable model involves a detailed analysis of potential confounding factors, and Dr. Aisen will present on the progress to date. In addition, Dr. Aisen will provide an update on the progress in the analysis of the Phase III clinical trial primary endpoint data. Some preliminary descriptive data shows numerical differences in favor of tramiprosate (ALZHEMED(TM)) on the primary clinical endpoint and also shows differences between groups on the primary disease modification endpoint as measured by magnetic resonance imaging (MRI). However, work regarding the adjustment of the statistical model is ongoing and, therefore results of the Phase III clinical trial cannot be derived from the preliminary data nor can statistical significance be assigned at this time. Accordingly, no predictions or conclusions can yet be made regarding the outcome of the Phase III study.






Page: 1 2 3 4

Related medicine technology :

1. Samaritans Alzheimers Drug Caprospinol Suggests Brain May be Able to Heal From Alzheimers Disease
2. Resveratrol Studies Suggest Broad Implications for SIRT1 Activation in Neurodegenerative Diseases of Aging Such as Alzheimers Disease
3. Accera, Inc. Announces Open-Label Data from Phase II Study in Alzheimers Disease at International Conference on Prevention of Dementia
4. Myriad Genetics Presents Mathematical Comparison of Disease Modification Trial Designs at Alzheimers ConferenceCurrent Flurizan Phase 3 Study Design May Demonstrate Disease Modification
5. Treating Heart Disease Risk Factors May Slow Alzheimers Disease Progression
6. Medivations Dimebon Maintains Statistically Significant Benefit on All Five Efficacy Endpoints in Alzheimers Disease Trial After One Year of Therapy
7. Clinical Update - Debio 9902 (ZT-1) for Alzheimers Disease
8. Medivation to Host Conference Call to Discuss Top-Line 12-Month Results From Dimebon Alzheimers Disease Study
9. Medivation Announces Presentation of New Subset Analyses From Dimebon Phase 2 Alzheimers Disease Trial at American Academy of Neurology Annual Meeting
10. Ceregene Presents Interim Phase 1 Clinical Data of CERE-110 for the Treatment of Alzheimers Disease
11. Samaritan Announces Positive Data in Nonclinical (IND) In-Vitro Studies for Promising Alzheimers Drug
Post Your Comments:
(Date:5/27/2015)... YORK , May 27, 2015 Protein ... source, based on differences in their physical properties. The ... the largest amount of functional protein with fewest contaminants. ... to grow at a CAGR of around 5% to ... driven by increased research in the pharmaceutical and biotechnological ...
(Date:5/27/2015)... 2015  Precision Advisors ( www.precisionadvisors.com ), a Precision ... Digital Trends Study of 145 managed care executives. The ... concepts of big data and predictive analytics, but are ... The Health Information Technology for Economic and Clinical Health ... use of electronic medical records (EMRs) by 2014. While ...
(Date:5/27/2015)... , May 27, 2015 ... announced the addition of the  "US Cancer ... their offering.       (Logo: http://photos.prnewswire.com/prnh/20130307/600769) ... into to two broad categories of prophylactic ... cancer vaccines belong to both of these ...
Breaking Medicine Technology:Protein Purification & Isolation Market by Technology by Product by Application & End User - Global Forecast to 2020 2Protein Purification & Isolation Market by Technology by Product by Application & End User - Global Forecast to 2020 3Precision Advisors Digital Trends Study: Less Than Half of Managed Care Organizations Have Access to Electronic Medical Records Data 2Precision Advisors Digital Trends Study: Less Than Half of Managed Care Organizations Have Access to Electronic Medical Records Data 3US Cancer Vaccine Market Outlook 2020 2US Cancer Vaccine Market Outlook 2020 3
... Corporation (NYSE: BSX ) announces that ... Stent System demonstrated non-inferior results in treating ... year compared to the PROMUS Element™ Everolimus-Eluting Platinum ... Use Trial.  The trial reported one-year clinical and ...
... May 15, 2012  InfuSystem Holdings, Inc. (NYSE MKT:  INFU), ... services for the healthcare industry, today announced that it ... Monday, May 21, 2012 following the market close.  ... call on Tuesday, May 22, 2012 at 9:00 a.m. ...
Cached Medicine Technology:One-Year EVOLVE Trial Clinical Results Confirm Comparable Safety And Effectiveness Data Of The Boston Scientific SYNERGY™ Stent Versus PROMUS Element™ Platinum Chromium Stent 2One-Year EVOLVE Trial Clinical Results Confirm Comparable Safety And Effectiveness Data Of The Boston Scientific SYNERGY™ Stent Versus PROMUS Element™ Platinum Chromium Stent 3One-Year EVOLVE Trial Clinical Results Confirm Comparable Safety And Effectiveness Data Of The Boston Scientific SYNERGY™ Stent Versus PROMUS Element™ Platinum Chromium Stent 4One-Year EVOLVE Trial Clinical Results Confirm Comparable Safety And Effectiveness Data Of The Boston Scientific SYNERGY™ Stent Versus PROMUS Element™ Platinum Chromium Stent 5One-Year EVOLVE Trial Clinical Results Confirm Comparable Safety And Effectiveness Data Of The Boston Scientific SYNERGY™ Stent Versus PROMUS Element™ Platinum Chromium Stent 6
(Date:5/27/2015)... Bedford, New Hampshire (PRWEB) May 27, 2015 ... published in the April 2015 issue of the Journal ... of diet sodas and abdominal obesity, Bedford Commons ... consuming water instead of non-nutritive sweetener-flavored beverages. , ... long-term waist circumference, a comprehensive San Antonio Longitudinal Study ...
(Date:5/27/2015)... The MedSpa at Hendrick is excited to ... in Abilene, Texas: Xeomin®, Belotero Balance® and Radiesse®. , ... lines, better known as the lines between the eyebrows ... treat smoker’s lines around the mouth and marionette lines ... the appearance of smile lines or lines around the ...
(Date:5/27/2015)... (PRWEB) May 27, 2015 CompanionDx ... pharmacogenomic and somatic genomic analysis in personalized cancer therapy: ... by the American Society of Clinical Oncology (ASCO) as ... 2 in Chicago. , The molecular and clinical data ... Genome Atlas (TCGA) database. The study reports improved patient ...
(Date:5/27/2015)... Cincinnati Veterans Affairs Women’s Health Clinic in ... Foundation is proud to host the first annual Women Veterans ... 11 at the Freedom Center from 6 p.m. to 10 ... emcee. , This event honors and celebrates women tri-state ... The banquet is free to the first 150 women Veterans ...
(Date:5/27/2015)... Rolling Meadows, IL (PRWEB) May 27, 2015 ... the release of its SonarMD Platform, a ... engaging, monitoring and managing patients with chronic ... Lawrence Kosinski, MD, MBA, the application allows ... between visits through the ongoing use of ...
Breaking Medicine News(10 mins):Health News:Recent Study About the Link Between Diet Sodas and Abdominal Fat Reinforces Bedford Commons OB-GYN's Recommendation to Drink Plenty of Water 2Health News:The MedSpa at Hendrick Introduces Xeomin®, Belotero Balance® and Radiesse® Injectables 2Health News:CompanionDx® Analyzes Non-small Cell Lung Cancer Data for Personalized Cancer Therapy 2Health News:CompanionDx® Analyzes Non-small Cell Lung Cancer Data for Personalized Cancer Therapy 3Health News:Cincinnati VA Women’s Health Clinic Celebrates Women Veterans at Awards Banquet 2Health News:SonarMD™, LLC, Launches Game-Changing, IBD Population Health Management Platform 2
... years or longer before currently available blood tests will detect ... of Medicine scientists indicates. The analysis, which was restricted to ... types, will be published online Nov. 16 in Science ... as both bad and good news," said Sanjiv "Sam" Gambhir, ...
... of Orthopaedic Surgeons (AAOS) Board of Directors has recently ... on "The Treatment of Supracondylar Humerus Fractures." ... of the Trauma Program at the University of Toronto ... AAOS Work Group responsible for this CPG, said that ...
... --- In 2020, the vast majority of adults in America ... suffer from diabetes or pre-diabetic conditions, according to projections presented ... Scientific Sessions Wednesday, Nov. 16, in Orlando. The ... overall heart health by 20 percent in 2020. However, if ...
... a breathtaking technological revolution that promises remarkable new ways ... the release of dangerous nanoparticles, nanorobots or nanoelectronic devices ... review of more than 500 studies on the topic ... ACS, journal Molecular Pharmaceutics . Ruth Duncan ...
... less produce the finest foie gras that rich, buttery ... eaten as slices atop lightly toasted bread scientists are ... and Food Chemistry. Caroline Molette and colleagues explain ... gras, a traditional French dish, comes from its high fat ...
... issues facing lesbian, gay, bisexual and transgender baby boomers ... These seniors face higher rates of disability, physical and ... according to the first study on aging and health ... and led by Karen Fredriksen-Goldsen and colleagues at the ...
Cached Medicine News:Health News:New Stanford model establishes guidelines for earlier cancer detection 2Health News:New Stanford model establishes guidelines for earlier cancer detection 3Health News:New Stanford model establishes guidelines for earlier cancer detection 4Health News:AAOS issues new clinical practice guideline for treating common elbow fractures in children 2Health News:On track to getting even fatter 2Health News:On track to getting even fatter 3Health News:LGBT seniors face harder old age, national study finds 2Health News:LGBT seniors face harder old age, national study finds 3
... versatility that a second mirror adds, then you ... It features the same 1.5x magnification as the ... 60 and 64 respectively. Available in standard (flange) ... the "Flanged" model for laser use. ...
... AFX (Air Fluid eXchange) Lens ... designed for use in an ... its use as a primary ... low profile and sutureless design ...
... The 15° Prism is ... pathologies and are recommended ... (PDR, BRVO etc.) and ... can be used for ...
... 15° Prism are designed for ... recommended for tractional retinal detachments ... retinal detachment. They can be ... other midperipheral laser applications. Direct ...
Medicine Products: